The importance of the CXCL12-CXCR4 chemokine ligand-receptor interaction in prostate cancer metastasis

Journal of Experimental Therapeutics and Oncology

Volumn 4, Issue 4, 2004, Pages 291-303

  Arya, Manit ^a,f   Patel, Hitendra R H ^b,c,d   McGurk, Claire ^a   Tatoud, Roger ^a   Klocker, Helmut ^e   Masters, John ^a   Williamson, Magali ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^f NONE   (United Kingdom)

Author keywords

Cancer; Chemokines; CXCR4; Metastasis; Prostate

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; STROMAL CELL DERIVED FACTOR 1;

ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL MIGRATION; CELL SURFACE; CHEMOTAXIS; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LASER MICRODISSECTION; LYMPH NODE METASTASIS; METASTASIS POTENTIAL; POLYMERASE CHAIN REACTION; POSTTRANSCRIPTIONAL GENE SILENCING; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CELL LINE, TUMOR; CELL MOVEMENT; CHEMOKINES, CXC; DNA PRIMERS; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHIDIUM; FLOW CYTOMETRY; HUMANS; LIGANDS; MALE; NEOPLASM METASTASIS; OLIGONUCLEOTIDES, ANTISENSE; PROSTATIC NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, CXCR4; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; RNA, MESSENGER;

EID: 13244269963     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Jensen OM, Esteve J, Moller H, Renard H. Cancer in the European Community and its member states. Eur J Cancer 1990; 26; 1167-1256.
2. Black RJ, Bray F, Ferlay J, Parkin DM. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer 1997; 33; 1075-1107.
3. Whitmore WF Jr. Natural history and staging of prostate cancer. Urol Clin North Am 1984; 11; 209-220.
4. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889; 1; 571-573.
5. Nicolson GL. Paracrine and autocrine growth mechanisms in tumor metastasis to specific sites with particular emphasis on brain and lung metastasis. Cancer Metastasis Rev 1993; 12; 325-343.
6. Stetler-Stevenson WG, Kleiner DE Jr. Molecular biology of cancer: invasion and metastases. In: Devita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2001: 123-136.
7. Walz A, Peveri P, Aschauer H, Baggiolini M. Purification and amino acid sequencing of NAF, a novel neutrophil-activating factor produced by monocytes. Biochem Biophys Res Commun 1987; 149; 755-761.
8. Yoshimura T, Matsushima K, Oppenheim JJ, Leonard EJ. Neutrophil chemotactic factor produced by lipopolysaccharide (LPS)-stimulated human blood mononuclear leucocytes: partial characterisation and separation from ilterleukin-1 (IL-1). J Immunol 1987; 139; 788-793.
9. Baggiolini M, Dewald B, Moser B. Interleukin-8 and related chemotactic cytokines - CXC and CC chemokines. Adv Immunol 1994; 55; 97-179
10. Baggiolini M, Dewald B, Moser B. Human chemokines: an update. Annu Rev Immunol 1997; 15; 675-705.
11. Murphy PM. The molecular biology of leukocyte chemoattractant receptors. Annu Rev Immunol 1994; 12; 593-633.
12. Murphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R, Matsushima K et al. International union of pharmacology. XXII. Nomenclature for chemokines receptors. Pharmacol Rev 2000; 52; 145-176.
13. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000; 18; 217-242.
14. Premack BA, Schall TJ. Chemokine receptors: gateways to inflammation and infection. Nat Med 1996; 2; 1174-1178.
15. Murphy PM. International Union of Pharmacology. XXX. Update on chemokine receptor nomenclature. Pharmacol Rev 2002; 54; 227-229.
16. Tashiro K, Tada H, Heilker R, Shirozu M, Nakano T, Honjo T. Signal sequence trap: a cloning strategy for secreted proteins and type 1 membrane proteins. Science (Washington DC) 1993; 261; 600-603.
17. Zhang XF, Wang JF, Matczak E, Proper J, Groopman JE. Janus kinase 2 is involved in stromal cell-derived factor-1-induced tyrosine phosphorylation of focal adhesion proteins and migration of hematopoietic progenitor cells. Blood 2001; 97; 3343-3348.
18. Bleul CC, Fuhlbrigge RC, Casanovas JM, Springer TA. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med. 1996; 184; 1101-1109.
19. Inngjerdingen M, Damaj B, Maghazachi AA. Expression and regulation of chemokine receptors in human natural killer cells. Blood 2001; 97; 367-375
20. Maghazachi AA. Role of the heterotrimeric G proteins in stromal-derived factor-1-induced natural killer cell chemotaxis and calcium mobilization. Biochem Biophys Res Commun. 1997; 236; 270-274.
21. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G-protein-coupled receptor. Science (London) 1996; 272; 872-877.
22. Loetscher M, Geiser T, O'Reilly T, Zwahlen R, Baggiolini M, Moser B. Cloning of a human seven-transmembrane domain receptor, LESTR, that is highly expressed in leukocytes. J Biol Chem. 1994; 269; 232-7.
23. Luster AD. Chemokines: chemotactic cytokines that mediate inflammation. N Engl J Med. 1998; 338; 436-445.
24. Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998; 393; 595-599.
25. Tachibana K, Hirota S, Iizasa H, Yoshida H, Kawabata K, Kataoka Y et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 1998; 393; 591-594.
26. Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kitamura Y et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 1996; 382; 635-638.
27. Ma Q, Jones D, Borghesani PR, Segal RA, Nagasawa T, Kishimoto T et al. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc Natl Acad Sci USA 1998; 95; 9448-9453.
28. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410; 50-6.
29. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol. 1979; 17; 16-23.
30. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF: Isolation of a human prostate carcinoma cell line (DU145). International Journal of Cancer 1978; 21; 274-281.
31. Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, Friedman M, Papsidero L et al. The LNCaP cell line-a new model for studies on human prostatic carcinoma. Prog Clin Biol Res. 1980; 37; 115-32.
32. Bright RK, Vocke CD, Emmert-Buck MR, Duray PH, Solomon D, Fetsch P et al. Generation and genetic characterization of immortal human prostate epithelial cell lines derived from primary cancer specimens. Cancer Res. 1997 1; 57; 995-1002
33. Stamps AC, Davies SC, Burman J, O'Hare MJ. Analysis of proviral integration in human mammary epithelial cell lines immortalized by retroviral infection with a temperature-sensitive SV40 T-antigen construct. Int J Cancer. 1994 15;57:865-74.
34. Alam TN, Daly-Burns B, Mackay A, O'Hare MJ, Masters JR, Hudosn DL. Early markers of epithelial cell differentiation in the human prostate. Abstract in Prostate Cancer and Prostatic Diseases 2001; 4: 183.
35. Mantovani A. Chemokines: introduction and overview. Chem Imunol 1999; 72; 1-6.
36. Mantovani A. The chemokine system: redundancy for robust outputs. Immunol Today 1999; 20; 254-257.
37. Rollins JB. Chemokines. Blood 1997; 90; 909-928.
38. Gerard C, Rollins BJ. Chemokines and disease. Nat Immunol. 2001; 2; 108-15.
39. Strieter RM. Chemokines: not just leukocyte chemoattractants in the promotion of cancer. Nat Immunol. 2001; 2; 285-286.
40. Baggiolini M. Chemokines in pathology and medicine. J Int Med. 2001; 250; 91-104.
41. Wang JM, Deng X, Gong W, Su S. Chemokines and their role in tumor growth and metastasis. J Immunol Methods 1998; 220; 1-17
42. Ardestani SK, Inserra P, Solkoff D, Watson RR. The role of cytokines and chemokines on tumor progression: a review. Cancer Detect Prev. 1999; 23; 215-225.
43. Cammack N. Human immunodeficiency virus type 1 entry and chemokine receptors: a new therapeutic target. Antivir Chem Chemother 1999; 10; 53-62.
44. Zhang YJ, Moore JP. Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type 1 entry? J Virol 1999; 73; 3443-3448.
45. Sehgal A, Keener C, Boynton AL, Warrick J, Murphy GP. CXCR-4, a chemokine receptor, is overexpressed in and required for proliferation of glioblastoma tumor cells. J Surg Oncol. 1998; 69; 99-104.
46. Sehgal A, Ricks S, Boynton AL, Warrick J, Murphy GP. Molecular characterization of CXCR-4: a potential brain tumor-associated gene. J Surg Oncol. 1998; 69; 239-248.
47. Gupta SK, Lysko PG, Pillarisetti K, Ohlstein E, Stadel JM. Chemokine receptors in human endothelial cells. Functional expression of CXCR4 and its transcriptional regulation by inflammatory cytokines. J Biol Chem. 1998; 273; 4282-4287.
48. Salcedo R, Wasserman K, Young HA, Grimm MC, Howard OM, Anver MR et al. Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: In vivo neovascularization induced by stromal-derived factor-1alpha. Am J Pathol. 1999; 154; 1125-1135.
49. Molino M, Woolkalis MJ, Prevost N, Pratico D, Barnathan ES, Taraboletti G et al. CXCR4 on human endothelial cells can serve as both a mediator of biological responses and as a receptor for HIV-2. Biochim Biophys Acta 2000; 1500; 227-240.
50. Germinder H, Sagi-Assif O, Goldberg L, Meshel T, Rechavi G, Witz IP et al. A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. J Immunol. 2001; 167; 4747-4757.
51. Koshiba T, Hosotani R, Miyamoto Y, Ida J, Tsuji S, Nakajima S et al. Expression of stromal cell-derived factor-1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumour progression. Clin Cancer Res. 2000; 6; 3530-3535.
52. Ponomaryov T, Peled A, Peled I, Taichman RS, Habler L, Sandbank J et al. Increased production of SDF-1 following treatment with DNA damaging agents: relevance for human stem cell homing and repopulation of NOD/ SCID mice. J Clin Investig. 2000; 106; 1331-1339.
53. Imai K, Kobayashi M, Wang J, Shinobu N, Yoshida H, Hamada J et al. Selective secretion of chemoattractants for haemopoietic progenitor cells by bone marrow endothelial cells: a possible role in homing of haemopoietic progenitor cells to bone marrow. Br J Haematol 1999; 106; 905-911.
54. Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP, Streiter RM. The stromal derived factor-1/ CXCL12 chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Resp and Crit Care Med. 2003; 167; 1676-1686.
55. Sun YX, Wang J, Shelburne CE, Lopatin DE, Chinnaiyan AM, Rubin MA et al. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem. 2003; 89; 462-73.
56. De Clercq E. Inhibition of HIV infection by bicyclams, highly potent and specific CXCR4 antagonists. Mol Pharmacol. 2000; 57; 833-839.
57. Hendrix CW, Flexner C, MacFarland RT, Giandomenico C, Fuchs EJ, Redpath E et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 2000; 44; 1667-1673.
58. Murakami T, Nakajima T, Koyanagi Y, Tachibana K, Fujii N, Tamamura H et al.A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J Exp Med. 1997; 186; 1389-1393.
59. Murakami T, Zhang TY, Koyanagi Y, Tanaka Y, Kim J, Suzuki Y et al. Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection. J Virol. 1999; 73; 7489-7496.
60. Arakaki R, Tamamura H, Premanathan M, Kanbara K, Ramanan S, Mochizuki K et al. T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure. J Virol 1999; 73; 1719-1723.
61. Doranz BJ, Grovit-Ferbas K, Sharron MP, Mao SH, Goetz MB, Daar ES et al. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J Exp Med. 1997; 186; 1395-1400.